NCT04374084

Brief Summary

This trial is designed to evaluate the efficacy and safety of moxibustion plus cupping in the convalescence of COVID-19.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for not_applicable covid19

Timeline
Completed

Started May 2020

Typical duration for not_applicable covid19

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 20, 2020

Completed
15 days until next milestone

First Posted

Study publicly available on registry

May 5, 2020

Completed
5 days until next milestone

Study Start

First participant enrolled

May 10, 2020

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2021

Completed
Last Updated

November 24, 2021

Status Verified

August 1, 2021

Enrollment Period

1.6 years

First QC Date

April 20, 2020

Last Update Submit

November 16, 2021

Conditions

Keywords

MoxibustionCOVID-19Randomized Clinical Trial

Outcome Measures

Primary Outcomes (1)

  • The proportion of responder at week 4

    The responder is defined as the participants with ≥ 50% average VAS decrease of chest tightness and fatigue compared with baseline. The VAS ranges from 0 to 100.

    baseline, week 4

Secondary Outcomes (15)

  • The proportion of responder at week 8

    baseline, week 8

  • The change in the average VAS score of main symptoms from baseline

    baseline, week 4, week 8

  • The change in the severity VAS score of main symptoms from baseline

    baseline, week 4, week 8

  • The change in the average VAS score of other symptoms from baseline

    baseline, week 4, week 8

  • The change in mean frequency of diarrhea and spontaneous bowel movements from baseline

    baseline, week 4, week 8

  • +10 more secondary outcomes

Study Arms (2)

Moxibustion plus Cupping

EXPERIMENTAL

Moxibustion plus cupping and basic therapy (rehabilitation direction and basic breathing exercise) once a day for 4 weeks (28 sessions).The moxibustion plus cupping treatments were divided into 2 alternating formulas: A: Monday, Wednesday, Friday and Sunday: moxibustion on bilateral Fengmen (BL12), Feishu (BL13) and Pishu(BL20) B: Tuesday, Thursday and Saturday: moxibustion on Zhongwan (RN12), Qihai (RN6), bilateral Tianshu(ST25) and Zusanli(ST36) + cupping on bilateral Feishu(BL13) Geshu(BL17) Pishu(BL20) The 2 formulas were used alternatively every other day, 7 times per week, for 4 weeks. Moxibustion acupoint addition: profuse sweating added Fuliu (KI7), insomnia added Shenmen(HT7) anxiety or depression added Neiguan (PC6).

Other: Moxibustion plus Cupping

Basic therapy

NO INTERVENTION

Basic therapy: rehabilitation direction and basic breathing exercise.

Interventions

Moxibustion: The burning of a small, thimble sized, smoldering plug of dried leaves on the skin at an acupuncture point. Usually the plugs contain leaves of mugwort or moxa. Cupping takes the pot as a tool, uses the combustion to remove the air in the pot, causes a negative pressure, and makes it adsorb on the skin of the acupoints. Use"Baixiaojiu"moxibustion on each acupoint for 10-15 minutes, the temperature of moxibustion should be adjusted within patient's tolerance level. Use diameter of 5-6 cm acuum cupper to cupping on each acupoint for 5-8 minutes.

Moxibustion plus Cupping

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Clinical diagnosis of the convalescence of COVID-19 (defined by the Chinese Guideline for COVID-19 in 2020 Trial Version 7).
  • years old;
  • chest tightness/fatigue/shortness of breath/cough, with at least 2 of the above symptoms and the average VAS score (last 48 hours) ≥ 40 points;
  • Volunteers with informed consent;

You may not qualify if:

  • Surgery in the lung that affects lung function;
  • Rely on mechanical ventilation to maintain lung function;
  • Chronic lung diseases affecting lung function;
  • Diseases affecting heart function;
  • Severe basic diseases;
  • Resting heart rate \> 120/min, systolic blood pressure \> 180mmHg, diastolic blood pressure \> 100mmHg;
  • Unstable angina or myocardial infarction in the past 1 month;
  • Severe obesity (BMI\>30kg/m2);
  • Allergic constitution;
  • Pregnant or lactating women;
  • Disabled patients;
  • Mentally ill Patients;
  • Participating in other clinical trials;
  • Poor compliance or other complicate conditions according to the researchers.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hubei Province Hospital

Wuhan, Hubei, China

RECRUITING

MeSH Terms

Conditions

COVID-19Convalescence

Interventions

Moxibustion

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract DiseasesDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Acupuncture TherapyComplementary TherapiesTherapeutics

Study Officials

  • Xiaopin Wang

    Guang'anmen Hospital of China Academy of Chinese Medical Sciences

    PRINCIPAL INVESTIGATOR
  • Zhongyu Zhou

    Hubei Hospital of Traditional Chinese Medicine

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Secretary of Guang'anmen Hospital of China Academy of Chinese Medical Sciences

Study Record Dates

First Submitted

April 20, 2020

First Posted

May 5, 2020

Study Start

May 10, 2020

Primary Completion

December 1, 2021

Study Completion

December 1, 2021

Last Updated

November 24, 2021

Record last verified: 2021-08

Data Sharing

IPD Sharing
Will share

Individual participant data are available on reasonable request. You can send e-mail to us if you have any question.

Shared Documents
STUDY PROTOCOL, SAP, ANALYTIC CODE
Time Frame
It depends.
Access Criteria
It depends.

Locations